Esperion Therapeutics
ESPR
Market cap $299M

1.51 USD

+0.04

2.72%

Updated Jul 30, 10:33 AM EDT

1 day

2.72%

5 days

13.53%

1 month

53.39%

3 months

51.09%

6 months

-16.57%

Year to date

-31.36%

1 year

-34.91%

5 years

-96.20%

10 years

-97.65%

About: Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Employees: 304

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

2% less repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 56

7% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 28

2% less funds holding

Funds holding: 188 [Q4 2024] → 185 (-3) [Q1 2025]

6.73% less ownership

Funds ownership: 63.97% [Q4 2024] → 57.24% (-6.73%) [Q1 2025]

41% less capital invested

Capital invested by funds: $277M [Q4 2024] → $164M (-$113M) [Q1 2025]

63% less call options, than puts

Call options by funds: $496K | Put options by funds: $1.36M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

165%

upside

Avg. target

$10

562%

upside

High target

$16

960%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis	960%upside $16	Buy Reiterated	17 Jun 2025
Needham Serge Belanger	165%upside $4	Buy Maintained	7 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ESPR published over the past 30 days

Zacks Investment Research

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion to Report Second Quarter 2025 Financial Results on August 5

ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.

Esperion to Report Second Quarter 2025 Financial Results on August 5

Esperion Appoints Craig Thompson to Board of Directors

Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience

Esperion Appoints Craig Thompson to Board of Directors

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Management projects profitability by Q1 2026, but I am wary given current revenue, cash, and expense guidance—profitability claims seem optimistic without a clear revenue boost. Pipeline developments, including a triple-combo LDL-C pill and liver/kidney therapies, could be transformative, but near-term catalysts hinge on execution and proof of profitability.

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

Zacks Investment Research

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs' Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET.

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with HLS Therapeutics (TSX:HLS) for the exclusive rights to commercialize NEXLETOL* and NEXLIZET* in Canada.

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

Zacks Investment Research

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year.

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

See News Rankings

Charts implemented using Lightweight Charts™